Balfaxar: Another Four-Factor PCC for Warfarin Reversal
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1696d ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Warfarin, Hemorrhage.
Abstract (Originalsprache)
Balfaxar (Octapharma), a human plasma-derived four-factor prothrombin complex concentrate (PCC), has been approved by the FDA for rapid reversal of warfarin anticoagulation in adults who require an urgent surgical/invasive procedure. It is the second four-factor PCC to become available in the US; Kcentra, which has been available since 2013, is approved for the same indication and for urgent reversal of warfarin anticoagulation in adults with acute major bleeding. Balfaxar is marketed in Canada and Europe as Octaplex.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2024). Balfaxar: Another Four-Factor PCC for Warfarin Reversal. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1696d
Vancouver
Balfaxar: Another Four-Factor PCC for Warfarin Reversal. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1696d
BibTeX
@article{euvimed2024,
title = {Balfaxar: Another Four-Factor PCC for Warfarin Reversal},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1696d}
}
EUVIMED